At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
MEDI9929, 140 mgdrug
Likely dose
MEDI9929, 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
In Brief
A Phase 1 clinical trial evaluating MEDI9929, 140 mg for Asthma. Completed, enrolled 21 participants across 4 sites.
Detailed Summary
To evaluate the PK profile of a single-dose of 140 mg subcutaneous (SC) administration of MEDI9929 (AMG 157) in adolescent subjects with mild to moderate asthma.
Study Details
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartSep 2015
Primary CompletionMay 2016
TodayJul 2026
First PostedJul 31, 2015
Enrollment StartSep 10, 2015
Primary CompletionMay 17, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.9 years ago
Interventions
MEDI9929, 140 mgdrug
On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.